Novartis FY2027 EPS Estimate Lowered by Erste Group Bank

Novartis AG (NYSE:NVS) – Equities researchers at Erste Group Bank decreased their FY2027 earnings per share estimates for shares of Novartis in a research note issued to investors on Wednesday, July 15th. Erste Group Bank analyst H. Engel now expects that the company will post earnings of $9.67 per share for the year, down from their previous estimate of $9.76. The consensus estimate for Novartis’ current full-year earnings is $8.76 per share.

Other equities analysts also recently issued research reports about the company. Morgan Stanley increased their price objective on Novartis from $143.00 to $170.00 and gave the stock an “overweight” rating in a report on Thursday, March 26th. Weiss Ratings cut shares of Novartis from a “buy (a-)” rating to a “buy (b)” rating in a report on Wednesday, April 29th. Seven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $141.20.

Novartis Trading Up 0.7%

NYSE NVS opened at $153.78 on Friday. The company has a quick ratio of 0.65, a current ratio of 0.85 and a debt-to-equity ratio of 0.96. Novartis has a twelve month low of $112.34 and a twelve month high of $170.46. The firm has a market capitalization of $293.44 billion, a PE ratio of 22.03, a P/E/G ratio of 2.63 and a beta of 0.45. The stock’s 50 day moving average is $151.41 and its 200 day moving average is $151.61.

Novartis (NYSE:NVS) last posted its earnings results on Monday, April 27th. The company reported $1.99 earnings per share for the quarter, missing analysts’ consensus estimates of $2.11 by ($0.12). Novartis had a return on equity of 38.82% and a net margin of 24.87%.The firm had revenue of $13.52 billion for the quarter, compared to analysts’ expectations of $13.44 billion. The firm’s revenue was down .9% on a year-over-year basis. During the same quarter last year, the company posted $2.28 EPS.

Hedge Funds Weigh In On Novartis

Hedge funds have recently added to or reduced their stakes in the company. Arlington Trust Co LLC purchased a new stake in Novartis during the fourth quarter valued at $25,000. Archer Investment Corp boosted its position in Novartis by 93.0% in the first quarter. Archer Investment Corp now owns 166 shares of the company’s stock worth $25,000 after purchasing an additional 80 shares during the last quarter. CrossGen Wealth LLC bought a new stake in shares of Novartis during the 4th quarter valued at about $28,000. Bank of Jackson Hole Trust grew its stake in shares of Novartis by 425.0% during the 4th quarter. Bank of Jackson Hole Trust now owns 231 shares of the company’s stock valued at $32,000 after purchasing an additional 187 shares during the period. Finally, Measured Wealth Private Client Group LLC purchased a new stake in shares of Novartis during the 3rd quarter valued at about $33,000. 13.12% of the stock is currently owned by hedge funds and other institutional investors.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.